Stratégies thérapeutiques actuelles du cancer de la prostate hormonorésistant

Translated title of the contribution: Current strategies in the management of hormone refractory prostate cancer

C. L. Martel, P. H. Gumerlock, Frederick J Meyers, Primo N Lara

Research output: Contribution to journalArticle

Abstract

Prostate cancer is the most common cancer diagnosed in American males, and is the second leading cause of cancer-related deaths. Most patients who develop metastatic disease will initially respond to androgen deprivation, but response is invariably temporary. Most patients will develop androgen-independent ("hormone-refractory") disease that results in progressive clinical deterioration and ultimately death. This progression to androgen independence is accompanied by increasingly evident DNA instability and alterations in genes and gene expression, including mutations in p53, over-expression of Bcl2, and mutations in the androgen receptor gene, among others. Treatment options for hormone-refractory disease include intensive supportive care, radiotherapy, bisphosphonates, second-line hormonal manipulations, cytotoxic chemotherapy and investigational agents. A post-treatment reduction in the level of prostate specific antigen (PSA) by 50% has been shown to correlate with survival and has been accepted by consensus as a valid endpoint in clinical trials. Chemotherapeutic agents such as mitoxantrone, estramustine, and the taxanes have yielded improved response rates and palliative benefit, but not improved survival. Therefore, current efforts must be focused on enrolling patients onto clinical trials of investigational agents with novel mechanisms of action, and on using survival, time to progression, and quality of life as end points in routine clinical practice.

Original languageFrench
Pages (from-to)85-102
Number of pages18
JournalAnnales d'Urologie
Volume38
Issue number3
DOIs
StatePublished - Jun 2004

Fingerprint

Androgens
Prostatic Neoplasms
Hormones
Survival
Estramustine
Clinical Trials
Taxoids
Mitoxantrone
Mutation
Diphosphonates
Androgen Receptors
Critical Care
Prostate-Specific Antigen
Genes
Neoplasms
Radiotherapy
Quality of Life
Gene Expression
Drug Therapy
DNA

Keywords

  • Cancer de la prostate
  • Chemotherapy
  • Chimiothérapie
  • Clinical trials
  • Essais cliniques
  • Hormone refractory
  • Hormonorésistant
  • Prostate cancer

ASJC Scopus subject areas

  • Urology

Cite this

Stratégies thérapeutiques actuelles du cancer de la prostate hormonorésistant. / Martel, C. L.; Gumerlock, P. H.; Meyers, Frederick J; Lara, Primo N.

In: Annales d'Urologie, Vol. 38, No. 3, 06.2004, p. 85-102.

Research output: Contribution to journalArticle

@article{cd04afbc58514eab83040956b6ce250b,
title = "Strat{\'e}gies th{\'e}rapeutiques actuelles du cancer de la prostate hormonor{\'e}sistant",
abstract = "Prostate cancer is the most common cancer diagnosed in American males, and is the second leading cause of cancer-related deaths. Most patients who develop metastatic disease will initially respond to androgen deprivation, but response is invariably temporary. Most patients will develop androgen-independent ({"}hormone-refractory{"}) disease that results in progressive clinical deterioration and ultimately death. This progression to androgen independence is accompanied by increasingly evident DNA instability and alterations in genes and gene expression, including mutations in p53, over-expression of Bcl2, and mutations in the androgen receptor gene, among others. Treatment options for hormone-refractory disease include intensive supportive care, radiotherapy, bisphosphonates, second-line hormonal manipulations, cytotoxic chemotherapy and investigational agents. A post-treatment reduction in the level of prostate specific antigen (PSA) by 50{\%} has been shown to correlate with survival and has been accepted by consensus as a valid endpoint in clinical trials. Chemotherapeutic agents such as mitoxantrone, estramustine, and the taxanes have yielded improved response rates and palliative benefit, but not improved survival. Therefore, current efforts must be focused on enrolling patients onto clinical trials of investigational agents with novel mechanisms of action, and on using survival, time to progression, and quality of life as end points in routine clinical practice.",
keywords = "Cancer de la prostate, Chemotherapy, Chimioth{\'e}rapie, Clinical trials, Essais cliniques, Hormone refractory, Hormonor{\'e}sistant, Prostate cancer",
author = "Martel, {C. L.} and Gumerlock, {P. H.} and Meyers, {Frederick J} and Lara, {Primo N}",
year = "2004",
month = "6",
doi = "10.1016/j.anuro.2004.04.001",
language = "French",
volume = "38",
pages = "85--102",
journal = "Annales d'Urologie",
issn = "0003-4401",
publisher = "Elsevier BV",
number = "3",

}

TY - JOUR

T1 - Stratégies thérapeutiques actuelles du cancer de la prostate hormonorésistant

AU - Martel, C. L.

AU - Gumerlock, P. H.

AU - Meyers, Frederick J

AU - Lara, Primo N

PY - 2004/6

Y1 - 2004/6

N2 - Prostate cancer is the most common cancer diagnosed in American males, and is the second leading cause of cancer-related deaths. Most patients who develop metastatic disease will initially respond to androgen deprivation, but response is invariably temporary. Most patients will develop androgen-independent ("hormone-refractory") disease that results in progressive clinical deterioration and ultimately death. This progression to androgen independence is accompanied by increasingly evident DNA instability and alterations in genes and gene expression, including mutations in p53, over-expression of Bcl2, and mutations in the androgen receptor gene, among others. Treatment options for hormone-refractory disease include intensive supportive care, radiotherapy, bisphosphonates, second-line hormonal manipulations, cytotoxic chemotherapy and investigational agents. A post-treatment reduction in the level of prostate specific antigen (PSA) by 50% has been shown to correlate with survival and has been accepted by consensus as a valid endpoint in clinical trials. Chemotherapeutic agents such as mitoxantrone, estramustine, and the taxanes have yielded improved response rates and palliative benefit, but not improved survival. Therefore, current efforts must be focused on enrolling patients onto clinical trials of investigational agents with novel mechanisms of action, and on using survival, time to progression, and quality of life as end points in routine clinical practice.

AB - Prostate cancer is the most common cancer diagnosed in American males, and is the second leading cause of cancer-related deaths. Most patients who develop metastatic disease will initially respond to androgen deprivation, but response is invariably temporary. Most patients will develop androgen-independent ("hormone-refractory") disease that results in progressive clinical deterioration and ultimately death. This progression to androgen independence is accompanied by increasingly evident DNA instability and alterations in genes and gene expression, including mutations in p53, over-expression of Bcl2, and mutations in the androgen receptor gene, among others. Treatment options for hormone-refractory disease include intensive supportive care, radiotherapy, bisphosphonates, second-line hormonal manipulations, cytotoxic chemotherapy and investigational agents. A post-treatment reduction in the level of prostate specific antigen (PSA) by 50% has been shown to correlate with survival and has been accepted by consensus as a valid endpoint in clinical trials. Chemotherapeutic agents such as mitoxantrone, estramustine, and the taxanes have yielded improved response rates and palliative benefit, but not improved survival. Therefore, current efforts must be focused on enrolling patients onto clinical trials of investigational agents with novel mechanisms of action, and on using survival, time to progression, and quality of life as end points in routine clinical practice.

KW - Cancer de la prostate

KW - Chemotherapy

KW - Chimiothérapie

KW - Clinical trials

KW - Essais cliniques

KW - Hormone refractory

KW - Hormonorésistant

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=2942643912&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2942643912&partnerID=8YFLogxK

U2 - 10.1016/j.anuro.2004.04.001

DO - 10.1016/j.anuro.2004.04.001

M3 - Article

AN - SCOPUS:2942643912

VL - 38

SP - 85

EP - 102

JO - Annales d'Urologie

JF - Annales d'Urologie

SN - 0003-4401

IS - 3

ER -